<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": Neurology: Protocol: 15061713 Antiviral therapy: Valacyclovir Treatment of Alzheimer’s" exact="Disease" post="(VALAD) Trial: protocol for a randomised, double-blind, placebo-controlled, treatment"/>
 <result pre="YorkNew YorkUSA[4], Department of Neurology, Taub Institute for Research on" exact="Alzheimer's Disease" post="and the Aging BrainColumbia University College of Physicians and"/>
 <result pre="YorkUSA[4], Department of Neurology, Taub Institute for Research on Alzheimer's" exact="Disease" post="and the Aging BrainColumbia University College of Physicians and"/>
 <result pre="the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.bmjopen-2019-032112.pdfbmjopen-2019-032112.reviewer_comments.pdfbmjopen-2019-032112.draft_revisions.pdf Abstract Introduction After infection," exact="herpes" post="simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion"/>
 <result pre="the trigeminal ganglion and can enter the brain via retrograde" exact="axonal" post="transport. Recurrent reactivation of HSV1 may lead to neurodegeneration"/>
 <result pre="ganglion and can enter the brain via retrograde axonal transport." exact="Recurrent" post="reactivation of HSV1 may lead to neurodegeneration and Alzheimer’s"/>
 <result pre="Recurrent reactivation of HSV1 may lead to neurodegeneration and Alzheimer’s" exact="disease" post="(AD) pathology. HSV1 (oral herpes) and HSV2 (genital herpes)"/>
 <result pre="with HSV seropositive, and antiviral drugs show robust efficacy against" exact="peripheral" post="HSV infection. Recent studies of electronic health records databases"/>
 <result pre="Recent studies of electronic health records databases demonstrate that HSV" exact="infections" post="increase dementia risk, and that antiviral medication treatment reduces"/>
 <result pre="of electronic health records databases demonstrate that HSV infections increase" exact="dementia" post="risk, and that antiviral medication treatment reduces this risk."/>
 <result pre="valacyclovir was superior to placebo in improving memory in a" exact="schizophrenia" post="pilot trial but has not been tested in AD."/>
 <result pre="puncture subsample, cerebrospinal fluid acyclovir will be assayed to assess" exact="central nervous system" post="valacyclovir penetration. Ethics and dissemination The trial is being"/>
 <result pre="Trial registration number ClinicalTrials.gov identifier (NCT03282916) Pre-results. virus valacyclovir Alzheimer’s" exact="disease" post="mild cognitive impairment biomarkers Funding http://dx.doi.org/10.13039/100000049National Institute on Aging"/>
 <result pre="number ClinicalTrials.gov identifier (NCT03282916) Pre-results. virus valacyclovir Alzheimer’s disease mild" exact="cognitive impairment" post="biomarkers Funding http://dx.doi.org/10.13039/100000049National Institute on Aging AG055422 Strengths and"/>
 <result pre="AG055422 Strengths and limitations of this study The association between" exact="herpes" post="simplex virus-1 (HSV1) and cognitive impairment meets several Bradford-Hill"/>
 <result pre="this study The association between herpes simplex virus-1 (HSV1) and" exact="cognitive impairment" post="meets several Bradford-Hill criteria suggesting a cause and effect"/>
 <result pre="randomised, double-blind, placebo-controlled trial of an antiviral treatment in Alzheimer’s" exact="disease" post="(AD) or any dementia that evaluates clinically relevant cognitive"/>
 <result pre="of an antiviral treatment in Alzheimer’s disease (AD) or any" exact="dementia" post="that evaluates clinically relevant cognitive and functional outcomes. Evaluation"/>
 <result pre="biomarkers: positron emission tomography amyloid and tau imaging indices, and" exact="secondary" post="measures of MRI cortical thinning, anti-HSV antibodies and odour"/>
 <result pre="amyloid and tau imaging indices, and secondary measures of MRI" exact="cortical" post="thinning, anti-HSV antibodies and odour identification impairment. A linear"/>
 <result pre="AD. Introduction Some viruses can cause neurodegenerative disorders, for example," exact="measles" post="virus infection can lead, years later, to subacute sclerosing"/>
 <result pre="Introduction Some viruses can cause neurodegenerative disorders, for example, measles" exact="virus infection" post="can lead, years later, to subacute sclerosing panencephalitis.1 Alzheimer’s"/>
 <result pre="Some viruses can cause neurodegenerative disorders, for example, measles virus" exact="infection" post="can lead, years later, to subacute sclerosing panencephalitis.1 Alzheimer’s"/>
 <result pre="for example, measles virus infection can lead, years later, to" exact="subacute" post="sclerosing panencephalitis.1 Alzheimer’s disease (AD) may be transmissible in"/>
 <result pre="infection can lead, years later, to subacute sclerosing panencephalitis.1 Alzheimer’s" exact="disease" post="(AD) may be transmissible in mice and primates, possibly"/>
 <result pre="mice and primates, possibly by a virus.2 3 The long-standing" exact="viral" post="aetiology hypothesis of AD posits that viruses in the"/>
 <result pre="hypothesis of AD posits that viruses in the brain, primarily" exact="herpes" post="simplex virus-1 (HSV1) (causes oral herpes) and possibly HSV2"/>
 <result pre="Effects of HSV on AD neuropathology In experimental studies, HSV1" exact="infection" post="of neuronal and glial cells triggers a decrease in"/>
 <result pre="HSV on AD neuropathology In experimental studies, HSV1 infection of" exact="neuronal" post="and glial cells triggers a decrease in amyloid precursor"/>
 <result pre="and HSV2 and account for the 10% of cases of" exact="herpes" post="simplex encephalitis (HSE) found to be caused by HSV2.11"/>
 <result pre="and account for the 10% of cases of herpes simplex" exact="encephalitis" post="(HSE) found to be caused by HSV2.11 In a"/>
 <result pre="latent HSV1 virus in the trigeminal ganglion, which is the" exact="primary" post="reservoir for HSV1 during latency, can occur decades after"/>
 <result pre="for HSV1 during latency, can occur decades after the original" exact="infection" post="with retrograde axonal transport of HSV1 particles infiltrating the"/>
 <result pre="latency, can occur decades after the original infection with retrograde" exact="axonal" post="transport of HSV1 particles infiltrating the locus coeruleus and"/>
 <result pre="the original infection with retrograde axonal transport of HSV1 particles" exact="infiltrating" post="the locus coeruleus and then progressing to the temporal"/>
 <result pre="predispose individuals to HSV reactivation.1 In patients with HSV seropositive," exact="viral" post="DNA was detected from nearly all combined postmortem tissue"/>
 <result pre="combined postmortem tissue samples of trigeminal and olfactory ganglia.14 Dendritic" exact="nerve" post="terminals of olfactory receptor neurons are directly exposed, and"/>
 <result pre="sequelae of anterograde memory loss, deficits in working memory and" exact="visual" post="object recognition, anosmia and dysphasia.16 The majority of HSE"/>
 <result pre="years old, possibly because blood–brain barrier disruption with ageing supports" exact="viral" post="entry. Clinically, antiviral treatment with acyclovir or valacyclovir is"/>
 <result pre="mortality and severity of cognitive deficits in HSE.16 HSV and" exact="cognitive impairment" post="The majority of older adults have had HSV infection"/>
 <result pre="cognitive impairment The majority of older adults have had HSV" exact="infection" post="during their lifetimes.17 Reactivation of HSV seropositivity immunoglobin M"/>
 <result pre="index has been shown to be higher in amnestic mild" exact="cognitive impairment" post="than healthy controls.19 ORs for the association between HSV1"/>
 <result pre="studies,18 20 with an OR of 2 reported in two" exact="Swedish" post="cohorts.21 22 In a series of 240 adults, HSV1"/>
 <result pre="series of 240 adults, HSV1 seropositivity was associated with a" exact="lower" post="neuropsychological test battery score and an 18-fold increase in"/>
 <result pre="18-fold increase in severe impairment in delayed memory.23 In a" exact="Finnish" post="study of 383 home-dwelling patients with cardiovascular disease, seropositivity"/>
 <result pre="memory.23 In a Finnish study of 383 home-dwelling patients with" exact="cardiovascular disease," post="seropositivity for HSV1, HSV2 or cytomegalovirus was associated with"/>
 <result pre="disease, seropositivity for HSV1, HSV2 or cytomegalovirus was associated with" exact="lower" post="Mini Mental State Exam (MMSE) scores and with decline"/>
 <result pre="Exam (MMSE) scores and with decline in MMSE and Clinical" exact="Dementia" post="Rating (CDR)24 scores during 1 year of follow-up. In that"/>
 <result pre="1 year of follow-up. In that study, with 0 to 1" exact="viral" post="seropositivities as reference, HRs for 2 and 3 viral"/>
 <result pre="1 viral seropositivities as reference, HRs for 2 and 3" exact="viral" post="seropositivities were 1.8 (95% CI 0.9 to 3.6) and"/>
 <result pre="2.3 (95% CI 1.1 to 5.0), respectively.25 In patients with" exact="psychotic disorders," post="impaired neurocognitive test performance has been associated with HSV1"/>
 <result pre="the associations between prior exposure to HSV, particularly HSV1, and" exact="cognitive impairment" post="are detectable in healthy older adults, patients with cardiovascular"/>
 <result pre="cognitive impairment are detectable in healthy older adults, patients with" exact="cardiovascular disease," post="and patients with psychotic disorders. Apolipoprotein E (apoE) ε4"/>
 <result pre="healthy older adults, patients with cardiovascular disease, and patients with" exact="psychotic disorders." post="Apolipoprotein E (apoE) ε4 genotype is a well-established risk"/>
 <result pre="a well-established risk factor for AD. In animal models, during" exact="acute" post="infection with HSV1, apoE ε4 seems to facilitate HSV1"/>
 <result pre="well-established risk factor for AD. In animal models, during acute" exact="infection" post="with HSV1, apoE ε4 seems to facilitate HSV1 latency"/>
 <result pre="ε3 and is more efficient than apoE ε3 in promoting" exact="viral" post="colonisation of the brain.28 In the brains of patients"/>
 <result pre="individuals, and apoE ε4 was more common in people with" exact="recurrent" post="cold sores than people without cold sores.29 These findings"/>
 <result pre="antiviral medication, is approved for the treatment of HSV1, HSV2," exact="herpes zoster" post="and chickenpox.30 No other antiviral drug, including acyclovir (intravenous),"/>
 <result pre="medication, is approved for the treatment of HSV1, HSV2, herpes" exact="zoster" post="and chickenpox.30 No other antiviral drug, including acyclovir (intravenous),"/>
 <result pre="converted in vivo to acyclovir, which is then converted by" exact="viral" post="thymidine kinase into its acyclovir monophosphate (acyclo-GMP) and acyclovir"/>
 <result pre="acyclovir triphosphate (acyclo-GTP) forms. Acyclo-GTP is a potent inhibitor of" exact="viral" post="DNA polymerase with 100 times higher affinity for viral"/>
 <result pre="of viral DNA polymerase with 100 times higher affinity for" exact="viral" post="than cellular polymerase.30 Viral enzymes cannot remove acyclo-GTP from"/>
 <result pre="with 100 times higher affinity for viral than cellular polymerase.30" exact="Viral" post="enzymes cannot remove acyclo-GTP from the chain, which results"/>
 <result pre="consequent chain termination. Its monophosphate form, acyclo-GMP, also incorporates into" exact="viral" post="DNA, leading to chain termination. Therefore, valacyclovir leads to"/>
 <result pre="side effect profile is benign. Valacyclovir has been tested in" exact="multiple sclerosis" post="(MS) with equivocal results. MS lesion size on brain"/>
 <result pre="a randomised, double-blind, placebo-controlled, 18-week trial in 24 patients with" exact="schizophrenia" post="with positive HSV1 titres, valacyclovir 3 g/day was superior to"/>
 <result pre="and 1.14 for tests of working memory, verbal memory and" exact="visual" post="object memory, respectively.33 These results are promising for the"/>
 <result pre="HSE, but controlled trials are lacking.16 Valacyclovir has a generally" exact="benign" post="safety profile with minimally higher rates of headache and"/>
 <result pre="to 7 years showed no major side effects.34 35 Hallucinations," exact="delirium" post="and seizures can occur in less than 1% of"/>
 <result pre="7 years showed no major side effects.34 35 Hallucinations, delirium" exact="and seizures" post="can occur in less than 1% of patients with"/>
 <result pre="years showed no major side effects.34 35 Hallucinations, delirium and" exact="seizures" post="can occur in less than 1% of patients with"/>
 <result pre="seizures can occur in less than 1% of patients with" exact="renal failure" post="who are taking valacyclovir.36 The recommended oral dose of"/>
 <result pre="are taking valacyclovir.36 The recommended oral dose of valacyclovir for" exact="peripheral" post="acute HSV infections is 1–3 g daily, and bioavailability is"/>
 <result pre="taking valacyclovir.36 The recommended oral dose of valacyclovir for peripheral" exact="acute" post="HSV infections is 1–3 g daily, and bioavailability is 54%.30"/>
 <result pre="The recommended oral dose of valacyclovir for peripheral acute HSV" exact="infections" post="is 1–3 g daily, and bioavailability is 54%.30 For long-term"/>
 <result pre="HSV suppression, the recommended dose is 1 g daily. In the" exact="schizophrenia" post="pilot trial that showed superiority for valacyclovir compared with"/>
 <result pre="dose range of 2–4 g daily for Valacyclovir Treatment of Alzheimer’s" exact="Disease" post="(VALAD). The dose range of 2–4 g daily is safe,"/>
 <result pre="Data Safety Monitoring Board. Recruitment, eligibility and consent The Memory" exact="Disorders" post="Centre at New York State Psychiatric Institute (NYSPI) and"/>
 <result pre="both of which are linked to the Columbia University Alzheimer’s" exact="Disease" post="Research Centre, are the main sources of recruitment. Over"/>
 <result pre="second site that recruits eligible patients presenting to their Memory" exact="Disorders" post="Programme. NYU conducts all clinical assessments, including neuropsychological testing,"/>
 <result pre="patients are conducted at Columbia University Medical Centre (CUMC). The" exact="total" post="sample size of 130 patients requires a recruitment rate"/>
 <result pre="or an AD CSF profile of low Aβ with high" exact="total" post="tau (tau, p-tau) levels based on the Aβ42/t-tau index"/>
 <result pre="memantine is permitted. Doses of these medications need to be" exact="stable" post="for at least 1 month prior to study entry. Psychotropic"/>
 <result pre="the study physician, to comply with study instructions. Patient has" exact="dementia" post="predominantly of the non-Alzheimer’s type, including vascular dementia, frontotemporal"/>
 <result pre="instructions. Patient has dementia predominantly of the non-Alzheimer’s type, including" exact="vascular dementia," post="frontotemporal dementia, Lewy body dementia, substance-induced dementia. Modified Hachinski"/>
 <result pre="has dementia predominantly of the non-Alzheimer’s type, including vascular dementia," exact="frontotemporal dementia," post="Lewy body dementia, substance-induced dementia. Modified Hachinski scale score"/>
 <result pre="predominantly of the non-Alzheimer’s type, including vascular dementia, frontotemporal dementia," exact="Lewy body dementia," post="substance-induced dementia. Modified Hachinski scale score greater than 4."/>
 <result pre="scale score greater than 4. Current clinical diagnosis of schizophrenia," exact="schizoaffective disorder," post="other psychosis, bipolar disorder or current major depression by"/>
 <result pre="4. Current clinical diagnosis of schizophrenia, schizoaffective disorder, other psychosis," exact="bipolar disorder" post="or current major depression by Diagnostic and Statistical Manual"/>
 <result pre="of schizophrenia, schizoaffective disorder, other psychosis, bipolar disorder or current" exact="major depression" post="by Diagnostic and Statistical Manual of Mental Disorders, 5th"/>
 <result pre="schizophrenia, schizoaffective disorder, other psychosis, bipolar disorder or current major" exact="depression" post="by Diagnostic and Statistical Manual of Mental Disorders, 5th"/>
 <result pre="of Mental Disorders, 5th Edition (DSM-5) criteria. Prior history of" exact="major depression" post="will not be exclusionary because 25% of older adults"/>
 <result pre="Mental Disorders, 5th Edition (DSM-5) criteria. Prior history of major" exact="depression" post="will not be exclusionary because 25% of older adults"/>
 <result pre="because 25% of older adults have a lifetime history of" exact="major depression." post="Active suicidal intent or plan based on clinical assessment."/>
 <result pre="clinical assessment. Current or recent (past 6 months) alcohol or" exact="substance use disorder" post="(DSM-5 criteria). Current diagnosis of other major neurological disorders,"/>
 <result pre="assessment. Current or recent (past 6 months) alcohol or substance" exact="use disorder" post="(DSM-5 criteria). Current diagnosis of other major neurological disorders,"/>
 <result pre="Current diagnosis of other major neurological disorders, including Parkinson’s disease," exact="multiple sclerosis," post="Huntington’s disease and amyotrophic lateral sclerosis. Clinical stroke with"/>
 <result pre="of other major neurological disorders, including Parkinson’s disease, multiple sclerosis," exact="Huntington’s disease" post="and amyotrophic lateral sclerosis. Clinical stroke with residual neurological"/>
 <result pre="other major neurological disorders, including Parkinson’s disease, multiple sclerosis, Huntington’s" exact="disease" post="and amyotrophic lateral sclerosis. Clinical stroke with residual neurological"/>
 <result pre="neurological disorders, including Parkinson’s disease, multiple sclerosis, Huntington’s disease and" exact="amyotrophic lateral sclerosis." post="Clinical stroke with residual neurological deficits. MRI findings of"/>
 <result pre="disorders, including Parkinson’s disease, multiple sclerosis, Huntington’s disease and amyotrophic" exact="lateral sclerosis." post="Clinical stroke with residual neurological deficits. MRI findings of"/>
 <result pre="disease, multiple sclerosis, Huntington’s disease and amyotrophic lateral sclerosis. Clinical" exact="stroke" post="with residual neurological deficits. MRI findings of cerebrovascular disease"/>
 <result pre="sclerosis. Clinical stroke with residual neurological deficits. MRI findings of" exact="cerebrovascular disease" post="(small infarcts, lacunes, periventricular disease) in the absence of"/>
 <result pre="Clinical stroke with residual neurological deficits. MRI findings of cerebrovascular" exact="disease" post="(small infarcts, lacunes, periventricular disease) in the absence of"/>
 <result pre="of cerebrovascular disease (small infarcts, lacunes, periventricular disease) in the" exact="absence of" post="clinical stroke with residual neurological deficits will not lead"/>
 <result pre="(small infarcts, lacunes, periventricular disease) in the absence of clinical" exact="stroke" post="with residual neurological deficits will not lead to exclusion."/>
 <result pre="months will be excluded, but past history of successfully treated" exact="cancer" post="will not lead to exclusion. Sitting blood pressure &amp;gt;160/100 mm"/>
 <result pre="will not lead to exclusion. Sitting blood pressure &amp;gt;160/100 mm Hg." exact="Renal failure" post="as determined by an estimated GFR &amp;lt;44 mL/min/1.73 m2. Serum vitamin"/>
 <result pre="vitamin B12 levels below the normal range. Patients with thrombotic" exact="thrombocytopenic" post="purpura/haemolytic uremic syndrome will be excluded (specific exclusion for"/>
 <result pre="below the normal range. Patients with thrombotic thrombocytopenic purpura/haemolytic uremic" exact="syndrome" post="will be excluded (specific exclusion for valacyclovir as per"/>
 <result pre="sample), this procedure will be conducted if there is no" exact="lower" post="spinal malformation or specific contraindication to LP such as"/>
 <result pre="PET Center Centre staff based on questionnaires and medical records." exact="Severe" post="vision or hearing impairment that would prevent the participant"/>
 <result pre="providing a valid performance on neuropsychological testing. Olfaction component: current" exact="upper respiratory infection" post="(patient tested as soon as this improves), current smoker"/>
 <result pre="a valid performance on neuropsychological testing. Olfaction component: current upper" exact="respiratory" post="infection (patient tested as soon as this improves), current"/>
 <result pre="valid performance on neuropsychological testing. Olfaction component: current upper respiratory" exact="infection" post="(patient tested as soon as this improves), current smoker"/>
 <result pre="40 is scored by chance in this multiple-choice test) indicating" exact="congenital" post="anosmia. Patients excluded from the olfaction component participate in"/>
 <result pre="study procedures. Aβ, amyloid beta-protein; AD, Alzheimer’s disease; CDR, Clinical" exact="Dementia" post="Rating; CSF, cerebrospinal fluid; FDA, Food and Drug Administration;"/>
 <result pre="FDA, Food and Drug Administration; GFR, glomerular filtration rate; HSV1," exact="herpes" post="simplex virus-1; LP, lumbar puncture; MMSE, Mini Mental Status"/>
 <result pre="is 55% women with 70% non-Hispanic White, 15% Hispanic, 12%" exact="African" post="American, and 3% Asian in origin. Exclusion criteria include"/>
 <result pre="lesions identified on MRI but without clinical deficits due to" exact="stroke" post="are included. Valacyclovir is excreted through the kidneys. A"/>
 <result pre="and/or memantine to treat AD, the dose needs to be" exact="stable" post="for 1 month prior to study entry. Psychotropic and other"/>
 <result pre="National Institute of Health supported phase II trials in AD." exact="Total" post="study duration is 5 years. Randomisation The NYSPI pharmacy"/>
 <result pre="study visits continue at scheduled time-points per the ITT principle." exact="Blindness" post="of raters Raters remain blind to randomised treatment condition"/>
 <result pre="time-points per the ITT principle. Blindness of raters Raters remain" exact="blind" post="to randomised treatment condition (valacyclovir or placebo). The blind"/>
 <result pre="remain blind to randomised treatment condition (valacyclovir or placebo). The" exact="blind" post="is not broken during the entire trial. In case"/>
 <result pre="conditions. Study measures At screening, blood is drawn to assess" exact="complete" post="blood count with differential, electrolytes, kidney functions, liver functions"/>
 <result pre="differential, electrolytes, kidney functions, liver functions and other tests (Sequential" exact="Multiple" post="Analysis—Computer), folate and vitamin B12 levels, thyroid functions and"/>
 <result pre="Analysis—Computer), folate and vitamin B12 levels, thyroid functions and serum" exact="viral" post="antibodies. Required visits and procedures are listed in table"/>
 <result pre="Table 1 Study procedures for the Valacyclovir Treatment of Alzheimer’s" exact="Disease" post="Trial Procedure Screening 0 weeks 2 weeks 4 weeks"/>
 <result pre="blood chemistry X       X X   X" exact="Complete" post="blood count with differential X       X"/>
 <result pre="light   X     X     X *CSF" exact="total" post="protein, glucose, cell count with differential   X  "/>
 <result pre="patients (n=52) who agree to CSF studies. ADAS-Cog 11, Alzheimer’s" exact="Disease" post="Assessment Scale – Cognitive Subscale 11; ADCS-ADL, Alzheimer’s Disease"/>
 <result pre="Alzheimer’s Disease Assessment Scale – Cognitive Subscale 11; ADCS-ADL, Alzheimer’s" exact="Disease" post="Cooperative Study-Activities of Daily Living; CDR, Clinical Dementia Rating;"/>
 <result pre="ADCS-ADL, Alzheimer’s Disease Cooperative Study-Activities of Daily Living; CDR, Clinical" exact="Dementia" post="Rating; CIBIC-plus, Clinician’s Interview-Based Impression of Change Plus Caregiver"/>
 <result pre="Impression of Change Plus Caregiver Input; CSF, cerebrospinal fluid; HSV," exact="herpes" post="simplex virus; MMSE, Mini Mental Status Examination; NACC/UDS, National"/>
 <result pre="Coordinating Center/Uniform Data Set; PET, positron emission tomography; SMAC, Sequential" exact="Multiple" post="Analysis- Computer; UPSIT, University of Pennsylvania Smell Identification Test."/>
 <result pre="Analysis- Computer; UPSIT, University of Pennsylvania Smell Identification Test. Alzheimer’s" exact="Disease" post="Assessment Scale-Cognition (ADAS-Cog11, modified version) includes tests of attention,"/>
 <result pre="memory that are given sequentially to reduce practice effects. Alzheimer’s" exact="Disease" post="Cooperative Study-Activities of Daily Living (ADCS-ADL) is a research"/>
 <result pre="0=none, 0.5=questionable, 1=mild, 2=moderate, 3=severe dementia. The study physician will" exact="complete" post="the NACC (Version 2) Forms that take 35–40 min and"/>
 <result pre="with assessment of Parkinsonian signs, psychiatric assessment that includes the" exact="short" post="version of the Geriatric Depression Scale and the Neuropsychiatric"/>
 <result pre="psychiatric assessment that includes the short version of the Geriatric" exact="Depression" post="Scale and the Neuropsychiatric Inventory, Functional Activities Questionnaire (administered"/>
 <result pre="the Neuropsychiatric Inventory, Functional Activities Questionnaire (administered to the caregiver)," exact="vascular" post="risk factors and the modified Hachinski ischaemic scale.45 Neuropsychological"/>
 <result pre="animals and vegetables, Craft Story21 immediate and delayed recall, Benson" exact="Complex" post="Figure Immediate and Delayed Recall, Trail Making A and"/>
 <result pre="Story21 immediate and delayed recall, Benson Complex Figure Immediate and" exact="Delayed" post="Recall, Trail Making A and B, Multilingual Naming Test,"/>
 <result pre="signs, physical examination, laboratory tests and contact with the patient’s" exact="primary" post="care physician as needed. Adverse events (AEs) are rated"/>
 <result pre="exposure to HSV1.46 Repeated reactivation leads to lifelong elevation of" exact="viral" post="titres, but they do not indicate duration or timing"/>
 <result pre="with the 22-gauge Sprotte needle, as specified on the Alzheimer’s" exact="Disease" post="Neuroimaging Initiative (ADNI) two website http://www.adni-info.org/Scientists/doc/ADNI2_Protocol_FINAL_20100917.pdf. At 12 and"/>
 <result pre="test.47The UPSIT comprises of four booklets, each with 10 odours." exact="Total" post="score is 0 to 40; score is 0 (incorrect)"/>
 <result pre="MRI hypothesis, we will examine the AD ‘signature’ of average" exact="cortical" post="thickness of 9 ROIs examined quantitatively by a cortical"/>
 <result pre="average cortical thickness of 9 ROIs examined quantitatively by a" exact="cortical" post="surface-based reconstruction and analysis.49 The 9 ROIs are medial"/>
 <result pre="lobule, supramarginal gyrus, precuneus and inferior frontal sulcus. Whole brain" exact="cortical" post="thickness will be an additional measure in the VALAD"/>
 <result pre="De-identified data are evaluated for adequacy; quality control checks include" exact="visual" post="inspection, assessment for excessive motion between frames, evaluation of"/>
 <result pre="of the tracer (injected activity 10 mCi). PET scans are" exact="acquired" post="in dynamic, 3D imaging mode beginning 50 min after injection."/>
 <result pre="in mild AD (medial orbital frontal, anterior cingulate, parietal, temporal," exact="posterior" post="cingulate, precuneus)50 will be the main outcome. For 18F-MK-6240"/>
 <result pre="18F-MK-6240 PET imaging (injected activity 5 mCi), PET scans are" exact="acquired" post="from 80 to 120 min after injection. Using similar processing"/>
 <result pre="lobes with cerebellar cortex as reference region. Tau aggregation is" exact="limited" post="to medial temporal cortex in older adults and does"/>
 <result pre="assistant/coordinator and the Principal Investigator to facilitate independent auditing of" exact="primary" post="subject records. The database will provide reports indicating all"/>
 <result pre="uptake in AD: medial orbital frontal, anterior cingulate, parietal, temporal," exact="posterior" post="cingulate, precuneus. Hypothesis 4. On tau PET scans (18F-MK-6240,"/>
 <result pre="to HSV1 and HSV2, MRI ‘signature’ in AD of regional" exact="cortical" post="thinning and whole brain cortical thinning,52 53 and CSF"/>
 <result pre="‘signature’ in AD of regional cortical thinning and whole brain" exact="cortical" post="thinning,52 53 and CSF acyclovir levels to examine plasma/CSF"/>
 <result pre="to LP. Statistical analysis and sample size There are two" exact="primary" post="outcome measures (multiple outcome measures): change in ADAS-Cog and"/>
 <result pre="unlike for co-primary outcome measures.54 All other outcome measures are" exact="secondary" post="or exploratory. Outcome measures 1. Primary: Change in ADAS-Cog11"/>
 <result pre="(cognition +function). 6. Exploratory: change in MRI AD ‘signature’ for" exact="cortical" post="thinning and whole brain cortical thinning, and serum antiviral"/>
 <result pre="in MRI AD ‘signature’ for cortical thinning and whole brain" exact="cortical" post="thinning, and serum antiviral antibody levels, and evaluation of"/>
 <result pre="guessing the next patient’s treatment. ITT/dropouts and missing data: The" exact="primary" post="analyses will be in the ITT sample, that is,"/>
 <result pre="one pre-measure and post-measure, inverse probability weighting of cases with" exact="complete" post="data will be used where weights are based on"/>
 <result pre="remaining drop out between 52 and 78 weeks, that is," exact="total" post="15% dropout by 78 weeks. We conducted power analysis"/>
 <result pre="a consent form that describes their role in the study." exact="Local" post="IRB and state regulations for consent are followed for"/>
 <result pre="suggested an antiviral treatment trial to potentially slow or arrest" exact="disease" post="progression in AD. VALAD is the first randomised, double-blind,"/>
 <result pre="peer reviewed. References References 1ItzhakiRF, LatheR, BalinBJ, et al.Microbes and" exact="Alzheimer's disease." post="J Alzheimers Dis2016;51:979–84. 10.3233/JAD-16015226967229 2BakerHF, RidleyRM, DuchenLW, et al.Induction"/>
 <result pre="References 1ItzhakiRF, LatheR, BalinBJ, et al.Microbes and Alzheimer's disease. J" exact="Alzheimers" post="Dis2016;51:979–84. 10.3233/JAD-16015226967229 2BakerHF, RidleyRM, DuchenLW, et al.Induction of β(A4)-amyloid"/>
 <result pre="et al.Induction of β(A4)-amyloid in primates by injection of Alzheimer’s" exact="disease" post="brain homogenate. Mol Neurobiol1994;8:25–39. 10.1007/BF027780058086126 3KaneMD, LipinskiWJ, CallahanMJ, et"/>
 <result pre="et al.Evidence for seeding of β-amyloid by intracerebral infusion of" exact="Alzheimer" post="brain extracts in β-amyloid precursor protein-transgenic mice. J. Neurosci.2000;20:3606–11."/>
 <result pre="β-amyloid precursor protein-transgenic mice. J. Neurosci.2000;20:3606–11. 10.1523/JNEUROSCI.20-10-03606.200010804202 4BallMJ&quot;Limbic Predilection in" exact="Alzheimer" post="Dementia: Is Reactivated Herpesvirus Involved?&quot;. Can. j. neurol. sci.1982;9:303–6."/>
 <result pre="immunosuppression. Psychol Med1986;16:247–9. 10.1017/S00332917000090533014587 6DevanandDPViral hypothesis and antiviral treatment in" exact="Alzheimer's disease." post="Curr Neurol Neurosci Rep2018;18:5510.1007/s11910-018-0863-130008124 7EimerWA, Vijaya KumarDK, Navalpur ShanmugamNK,"/>
 <result pre="by herpesviridae to protect against brain infection. Neuron2018;99:56–63. 10.1016/j.neuron.2018.06.03030001512 8CarterCJAlzheimer's" exact="disease" post="plaques and tangles: Cemeteries of a pyrrhic victory of"/>
 <result pre="of a pyrrhic victory of the immune defence network against" exact="herpes" post="simplex infection at the expense of complement and inflammation-mediated"/>
 <result pre="pyrrhic victory of the immune defence network against herpes simplex" exact="infection" post="at the expense of complement and inflammation-mediated neuronal destruction."/>
 <result pre="herpes simplex infection at the expense of complement and inflammation-mediated" exact="neuronal" post="destruction. Neurochem Int2011;58:301–20. 10.1016/j.neuint.2010.12.00321167244 9WozniakMA, MeeAP, ItzhakiRFHerpes simplex virus"/>
 <result pre="neuronal destruction. Neurochem Int2011;58:301–20. 10.1016/j.neuint.2010.12.00321167244 9WozniakMA, MeeAP, ItzhakiRFHerpes simplex virus" exact="type 1" post="DNA is located within Alzheimer's disease amyloid plaques. J"/>
 <result pre="MeeAP, ItzhakiRFHerpes simplex virus type 1 DNA is located within" exact="Alzheimer's disease" post="amyloid plaques. J Pathol2009;217:131–8. 10.1002/path.244918973185 10KristenH, SantanaS, SastreI, et"/>
 <result pre="ItzhakiRFHerpes simplex virus type 1 DNA is located within Alzheimer's" exact="disease" post="amyloid plaques. J Pathol2009;217:131–8. 10.1002/path.244918973185 10KristenH, SantanaS, SastreI, et"/>
 <result pre="J Pathol2009;217:131–8. 10.1002/path.244918973185 10KristenH, SantanaS, SastreI, et al.Herpes simplex virus" exact="type 2" post="infection induces AD-like neurodegeneration markers in human neuroblastoma cells."/>
 <result pre="10.1002/path.244918973185 10KristenH, SantanaS, SastreI, et al.Herpes simplex virus type 2" exact="infection" post="induces AD-like neurodegeneration markers in human neuroblastoma cells. Neurobiol"/>
 <result pre="virus type 2 infection induces AD-like neurodegeneration markers in human" exact="neuroblastoma" post="cells. Neurobiol Aging2015;36:2737–47. 10.1016/j.neurobiolaging.2015.06.01426163986 11BurgosJS, RamirezC, SastreI, et al.Involvement"/>
 <result pre="et al.Involvement of apolipoprotein E in the hematogenous route of" exact="herpes" post="simplex virus type 1 to the central nervous system."/>
 <result pre="apolipoprotein E in the hematogenous route of herpes simplex virus" exact="type 1" post="to the central nervous system. J Virol2002;76:12394–8. 10.1128/JVI.76.23.12394-12398.200212414984 12WozniakMA,"/>
 <result pre="hematogenous route of herpes simplex virus type 1 to the" exact="central nervous system." post="J Virol2002;76:12394–8. 10.1128/JVI.76.23.12394-12398.200212414984 12WozniakMA, FrostAL, PrestonCM, et al.Antivirals reduce"/>
 <result pre="12WozniakMA, FrostAL, PrestonCM, et al.Antivirals reduce the formation of key" exact="Alzheimer's disease" post="molecules in cell cultures acutely infected with herpes simplex"/>
 <result pre="FrostAL, PrestonCM, et al.Antivirals reduce the formation of key Alzheimer's" exact="disease" post="molecules in cell cultures acutely infected with herpes simplex"/>
 <result pre="key Alzheimer's disease molecules in cell cultures acutely infected with" exact="herpes" post="simplex virus type 1. PLoS One2011;6:e2515210.1371/journal.pone.002515222003387 13SteinerI, KennedyPGE, PachnerARThe"/>
 <result pre="molecules in cell cultures acutely infected with herpes simplex virus" exact="type 1." post="PLoS One2011;6:e2515210.1371/journal.pone.002515222003387 13SteinerI, KennedyPGE, PachnerARThe neurotropic herpes viruses: herpes"/>
 <result pre="simplex virus type 1. PLoS One2011;6:e2515210.1371/journal.pone.002515222003387 13SteinerI, KennedyPGE, PachnerARThe neurotropic" exact="herpes" post="viruses: herpes simplex and varicella-zoster. Lancet Neurol2007;6:1015–28. 10.1016/S1474-4422(07)70267-317945155 14LiedtkeW,"/>
 <result pre="type 1. PLoS One2011;6:e2515210.1371/journal.pone.002515222003387 13SteinerI, KennedyPGE, PachnerARThe neurotropic herpes viruses:" exact="herpes" post="simplex and varicella-zoster. Lancet Neurol2007;6:1015–28. 10.1016/S1474-4422(07)70267-317945155 14LiedtkeW, OpalkaB, ZimmermannCW,"/>
 <result pre="Neurol2007;6:1015–28. 10.1016/S1474-4422(07)70267-317945155 14LiedtkeW, OpalkaB, ZimmermannCW, et al.Age distribution of latent" exact="herpes" post="simplex virus 1 and varicella-zoster virus genome in human"/>
 <result pre="of neurotropic viruses. J Neurovirol2005;11:129–37. 10.1080/1355028059092279316036791 16HokkanenL, LaunesJCognitive outcome in" exact="acute" post="sporadic encephalitis. Neuropsychol Rev2000;10:151–67. 10.1023/A:100907953119610983899 17XuF, SternbergMR, KottiriBJ, et"/>
 <result pre="encephalitis. Neuropsychol Rev2000;10:151–67. 10.1023/A:100907953119610983899 17XuF, SternbergMR, KottiriBJ, et al.Trends in" exact="herpes" post="simplex virus type 1 and type 2 seroprevalence in"/>
 <result pre="10.1023/A:100907953119610983899 17XuF, SternbergMR, KottiriBJ, et al.Trends in herpes simplex virus" exact="type 1" post="and type 2 seroprevalence in the United States. JAMA2006;296:964–73."/>
 <result pre="KottiriBJ, et al.Trends in herpes simplex virus type 1 and" exact="type 2" post="seroprevalence in the United States. JAMA2006;296:964–73. 10.1001/jama.296.8.96416926356 18LetenneurL, PérèsK,"/>
 <result pre="United States. JAMA2006;296:964–73. 10.1001/jama.296.8.96416926356 18LetenneurL, PérèsK, FleuryH, et al.Seropositivity to" exact="herpes" post="simplex virus antibodies and risk of Alzheimer's disease: a"/>
 <result pre="ShinagawaS, et al.Increase in the IgG avidity index due to" exact="herpes" post="simplex virus type 1 reactivation and its relationship with"/>
 <result pre="in the IgG avidity index due to herpes simplex virus" exact="type 1" post="reactivation and its relationship with cognitive function in amnestic"/>
 <result pre="reactivation and its relationship with cognitive function in amnestic mild" exact="cognitive impairment" post="and Alzheimer's disease. Biochem Biophys Res Commun2013;430:907–11. 10.1016/j.bbrc.2012.12.05423261465 20ItzhakiRFHerpes"/>
 <result pre="relationship with cognitive function in amnestic mild cognitive impairment and" exact="Alzheimer's disease." post="Biochem Biophys Res Commun2013;430:907–11. 10.1016/j.bbrc.2012.12.05423261465 20ItzhakiRFHerpes simplex virus type"/>
 <result pre="Alzheimer's disease. Biochem Biophys Res Commun2013;430:907–11. 10.1016/j.bbrc.2012.12.05423261465 20ItzhakiRFHerpes simplex virus" exact="type 1" post="and Alzheimer's disease: increasing evidence for a major role"/>
 <result pre="virus. Front Aging Neurosci2014;6:20210.3389/fnagi.2014.0020225157230 21LövheimH, GilthorpeJ, JohanssonA, et al.Herpes simplex" exact="infection" post="and the risk of Alzheimer's disease: a nested case-control"/>
 <result pre="and the risk of Alzheimer's disease: a nested case-control study." exact="Alzheimers" post="Dement2015;11:587–92. 10.1016/j.jalz.2014.07.15725304990 22LövheimH, GilthorpeJ, AdolfssonR, et al.Reactivated herpes simplex"/>
 <result pre="case-control study. Alzheimers Dement2015;11:587–92. 10.1016/j.jalz.2014.07.15725304990 22LövheimH, GilthorpeJ, AdolfssonR, et al.Reactivated" exact="herpes" post="simplex infection increases the risk of Alzheimer's disease. Alzheimers"/>
 <result pre="Alzheimers Dement2015;11:587–92. 10.1016/j.jalz.2014.07.15725304990 22LövheimH, GilthorpeJ, AdolfssonR, et al.Reactivated herpes simplex" exact="infection" post="increases the risk of Alzheimer's disease. Alzheimers Dement2015;11:593–9. 10.1016/j.jalz.2014.04.52225043910"/>
 <result pre="AdolfssonR, et al.Reactivated herpes simplex infection increases the risk of" exact="Alzheimer's disease." post="Alzheimers Dement2015;11:593–9. 10.1016/j.jalz.2014.04.52225043910 23DickersonF, StallingsC, SullensA, et al.Association between"/>
 <result pre="al.Reactivated herpes simplex infection increases the risk of Alzheimer's disease." exact="Alzheimers" post="Dement2015;11:593–9. 10.1016/j.jalz.2014.04.52225043910 23DickersonF, StallingsC, SullensA, et al.Association between cognitive"/>
 <result pre="23DickersonF, StallingsC, SullensA, et al.Association between cognitive functioning, exposure to" exact="herpes" post="simplex virus type 1, and the COMT Val158Met genetic"/>
 <result pre="et al.Association between cognitive functioning, exposure to herpes simplex virus" exact="type 1," post="and the COMT Val158Met genetic polymorphism in adults without"/>
 <result pre="and the COMT Val158Met genetic polymorphism in adults without a" exact="psychiatric disorder." post="Brain Behav Immun2008;22:1103–7. 10.1016/j.bbi.2008.04.15618571372 24BurkeWJ, MillerJP, RubinEH, et al.Reliability"/>
 <result pre="COMT Val158Met genetic polymorphism in adults without a psychiatric disorder." exact="Brain" post="Behav Immun2008;22:1103–7. 10.1016/j.bbi.2008.04.15618571372 24BurkeWJ, MillerJP, RubinEH, et al.Reliability of"/>
 <result pre="24BurkeWJ, MillerJP, RubinEH, et al.Reliability of the Washington University clinical" exact="dementia" post="rating. Arch Neurol1988;45:31–2. 10.1001/archneur.1988.005202500370153337672 25StrandbergTE, PitkalaKH, LinnavuoriKH, et al.Impact"/>
 <result pre="rating. Arch Neurol1988;45:31–2. 10.1001/archneur.1988.005202500370153337672 25StrandbergTE, PitkalaKH, LinnavuoriKH, et al.Impact of" exact="viral" post="and bacterial burden on cognitive impairment in elderly persons"/>
 <result pre="Neurol1988;45:31–2. 10.1001/archneur.1988.005202500370153337672 25StrandbergTE, PitkalaKH, LinnavuoriKH, et al.Impact of viral and" exact="bacterial" post="burden on cognitive impairment in elderly persons with cardiovascular"/>
 <result pre="PitkalaKH, LinnavuoriKH, et al.Impact of viral and bacterial burden on" exact="cognitive impairment" post="in elderly persons with cardiovascular diseases. Stroke2003;34:2126–31. 10.1161/01.STR.0000086754.32238.DA12920256 26DickersonFB,"/>
 <result pre="and bacterial burden on cognitive impairment in elderly persons with" exact="cardiovascular" post="diseases. Stroke2003;34:2126–31. 10.1161/01.STR.0000086754.32238.DA12920256 26DickersonFB, BoronowJJ, StallingsC, et al.Association of"/>
 <result pre="10.1161/01.STR.0000086754.32238.DA12920256 26DickersonFB, BoronowJJ, StallingsC, et al.Association of serum antibodies to" exact="herpes" post="simplex virus 1 with cognitive deficits in individuals with"/>
 <result pre="schizophrenia. Arch Gen Psychiatry2003;60:466–72. 10.1001/archpsyc.60.5.46612742867 27WatsonAMM, PrasadKM, KleiL, et al.Persistent" exact="infection" post="with neurotropic herpes viruses and cognitive impairment. Psychol Med2013;43:1023–31."/>
 <result pre="Psychiatry2003;60:466–72. 10.1001/archpsyc.60.5.46612742867 27WatsonAMM, PrasadKM, KleiL, et al.Persistent infection with neurotropic" exact="herpes" post="viruses and cognitive impairment. Psychol Med2013;43:1023–31. 10.1017/S003329171200195X22975221 28BurgosJS, RamirezC,"/>
 <result pre="PrasadKM, KleiL, et al.Persistent infection with neurotropic herpes viruses and" exact="cognitive impairment." post="Psychol Med2013;43:1023–31. 10.1017/S003329171200195X22975221 28BurgosJS, RamirezC, SastreI, et al.Effect of"/>
 <result pre="28BurgosJS, RamirezC, SastreI, et al.Effect of apolipoprotein E on the" exact="cerebral" post="load of latent herpes simplex virus type 1 DNA."/>
 <result pre="al.Effect of apolipoprotein E on the cerebral load of latent" exact="herpes" post="simplex virus type 1 DNA. J Virol2006;80:5383–7. 10.1128/JVI.00006-0616699018 29ItzhakiRF,"/>
 <result pre="E on the cerebral load of latent herpes simplex virus" exact="type 1" post="DNA. J Virol2006;80:5383–7. 10.1128/JVI.00006-0616699018 29ItzhakiRF, LinW-R, ShangD, et al.Herpes"/>
 <result pre="J Virol2006;80:5383–7. 10.1128/JVI.00006-0616699018 29ItzhakiRF, LinW-R, ShangD, et al.Herpes simplex virus" exact="type 1" post="in brain and risk of Alzheimer's disease. The Lancet1997;349:241–4."/>
 <result pre="al.Herpes simplex virus type 1 in brain and risk of" exact="Alzheimer's disease." post="The Lancet1997;349:241–4. 10.1016/S0140-6736(96)10149-5 30BeutnerKRValacyclovir: a review of its antiviral"/>
 <result pre="ZabriskieJB, PlankC, et al.A randomized clinical trial of valacyclovir in" exact="multiple sclerosis." post="Mult Scler2005;11:286–95. 10.1191/1352458505ms1185oa15957509 33PrasadKM, EackSM, KeshavanMS, et al.Antiherpes virus–specific"/>
 <result pre="Acyclovir. J Infect Dis2002;186:S40–6. 10.1086/34296612353186 35Vere HodgeRA, FieldHJAntiviral agents for" exact="herpes" post="simplex virus. Adv Pharmacol2013;67:1–38. 10.1016/B978-0-12-405880-4.00001-923885997 36AsahiT, TsutsuiM, WakasugiM, et"/>
 <result pre="Chemother2003;47:2438–41. 10.1128/AAC.47.8.2438-2441.200312878501 38AlbertMS, DeKoskyST, DicksonD, et al.The diagnosis of mild" exact="cognitive impairment" post="due to Alzheimer's disease: recommendations from the National Institute"/>
 <result pre="National Institute on Aging-Alzheimer's association workgroups on diagnostic guidelines for" exact="Alzheimer's disease." post="Alzheimers Dement2011;7:270–9. 10.1016/j.jalz.2011.03.00821514249 39LamNN, WeirMA, YaoZ, et al.Risk of"/>
 <result pre="on Aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease." exact="Alzheimers" post="Dement2011;7:270–9. 10.1016/j.jalz.2011.03.00821514249 39LamNN, WeirMA, YaoZ, et al.Risk of acute"/>
 <result pre="disease. Alzheimers Dement2011;7:270–9. 10.1016/j.jalz.2011.03.00821514249 39LamNN, WeirMA, YaoZ, et al.Risk of" exact="acute" post="kidney injury from oral acyclovir: a population-based study. Am"/>
 <result pre="Alzheimers Dement2011;7:270–9. 10.1016/j.jalz.2011.03.00821514249 39LamNN, WeirMA, YaoZ, et al.Risk of acute" exact="kidney injury" post="from oral acyclovir: a population-based study. Am J Kidney"/>
 <result pre="kidney injury from oral acyclovir: a population-based study. Am J" exact="Kidney" post="Dis2013;61:723–9. 10.1053/j.ajkd.2012.12.00823312723 40WangLH, SchultzM, WellerS, et al.Pharmacokinetics and safety"/>
 <result pre="Clin Climatol Assoc2009;120:419.19768194 42RosenWG, MohsRC, DavisKLA new rating scale for" exact="Alzheimer's disease." post="Am J Psychiatry1984;141:1356-6410.1176/ajp.141.11.13566496779 43SchneiderLSAssessing outcomes in Alzheimer disease. Alzheimer"/>
 <result pre="scale for Alzheimer's disease. Am J Psychiatry1984;141:1356-6410.1176/ajp.141.11.13566496779 43SchneiderLSAssessing outcomes in" exact="Alzheimer disease." post="Alzheimer Dis Assoc Disord2001;15:S8–18. 10.1097/00002093-200108001-0000311669509 44RogersSL, FarlowMR, DoodyRS, et"/>
 <result pre="Alzheimer's disease. Am J Psychiatry1984;141:1356-6410.1176/ajp.141.11.13566496779 43SchneiderLSAssessing outcomes in Alzheimer disease." exact="Alzheimer" post="Dis Assoc Disord2001;15:S8–18. 10.1097/00002093-200108001-0000311669509 44RogersSL, FarlowMR, DoodyRS, et al.A"/>
 <result pre="al.A 24-week, double-blind, placebo-controlled trial of donepezil in patients with" exact="Alzheimer's disease." post="Neurology1998;50:136–45. 10.1212/WNL.50.1.1369443470 45LinM, GongP, YangT, et al.Big data analytical"/>
 <result pre="analytical approaches to the NACC dataset: aiding preclinical trial enrichment." exact="Alzheimer" post="Dis Assoc Disord2018;32:1810.1097/WAD.000000000000022829227306 46BergströmT, TrybalaEAntigenic differences between HSV-1 and"/>
 <result pre="10.1016/j.jneumeth.2004.07.01415652618 49DickersonBC, FeczkoE, AugustinackJC, et al.Differential effects of aging and" exact="Alzheimer's disease" post="on medial temporal lobe cortical thickness and surface area."/>
 <result pre="49DickersonBC, FeczkoE, AugustinackJC, et al.Differential effects of aging and Alzheimer's" exact="disease" post="on medial temporal lobe cortical thickness and surface area."/>
 <result pre="et al.Differential effects of aging and Alzheimer's disease on medial" exact="temporal lobe" post="cortical thickness and surface area. Neurobiol Aging2009;30:432–40. 10.1016/j.neurobiolaging.2007.07.02217869384 50VillemagneVL,"/>
 <result pre="effects of aging and Alzheimer's disease on medial temporal lobe" exact="cortical" post="thickness and surface area. Neurobiol Aging2009;30:432–40. 10.1016/j.neurobiolaging.2007.07.02217869384 50VillemagneVL, DoréV,"/>
 <result pre="(NFTs). J Med Chem2016;59:4778–89. 10.1021/acs.jmedchem.6b0016627088900 52DickersonBC, BakkourA, SalatDH, et al.The" exact="cortical" post="signature of Alzheimer's disease: regionally specific cortical thinning relates"/>
 <result pre="SalatDH, et al.The cortical signature of Alzheimer's disease: regionally specific" exact="cortical" post="thinning relates to symptom severity in very mild to"/>
 <result pre="relates to symptom severity in very mild to mild AD" exact="dementia" post="and is detectable in asymptomatic amyloid-positive individuals. Cerebral Cortex2009;19:497–510."/>
 <result pre="mild AD dementia and is detectable in asymptomatic amyloid-positive individuals." exact="Cerebral" post="Cortex2009;19:497–510. 10.1093/cercor/bhn11318632739 53DickersonB, WolkDBiomarker-Based prediction of progression in MCI:"/>
 <result pre="p-value adjustment?BMC Med Res Methodol2002;2:810.1186/1471-2288-2-812069695 55PodhornaJ, KrahnkeT, ShearM, et al.Alzheimer's" exact="disease" post="assessment Scale-Cognitive subscale variants in mild cognitive impairment and"/>
 <result pre="ShearM, et al.Alzheimer's disease assessment Scale-Cognitive subscale variants in mild" exact="cognitive impairment" post="and mild Alzheimer's disease: change over time and the"/>
 <result pre="disease: change over time and the effect of enrichment strategies." exact="Alzheimers" post="Res Ther2016;8:810.1186/s13195-016-0170-526868820"/>
</results>
